Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 AcquisitionLawrence Corey, Myron S. Cohen, Robinson Cabello et al.|New England Journal of Medicine|2021Cited by 540
Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19)Dan H. Barouch, Ludo Lavreys, Frank Tomaka et al.|The Lancet|2018Cited by 342
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in AdultsGlenda Gray, Lubbe Wiesner, Linda‐Gail Bekker et al.|New England Journal of Medicine|2021Cited by 231
Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trialGlenda Gray, Mookho Malahleha, Kathryn Mngadi et al.|The Lancet Infectious Diseases|2024Cited by 40
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participantsCatherine Riou, Helen Rees, Jinal N. Bhiman et al.|PLOS Global Public Health|2024Cited by 12